Core Viewpoint - The company has signed a strategic cooperation agreement with Kiang Wu Hospital in Macau to establish a comprehensive brain health service model, focusing on digital screening, assessment, training, and health management for cognitive disorders. Group 1: Cooperation Details - The partnership will create a "Brain Health Center" within Kiang Wu Hospital, offering a one-stop service from early screening to digital cognitive training and follow-up care [1] - Services will cater to all age groups, including individuals aged 60 and above at risk of cognitive disorders and children aged 3 to 18 with neurodevelopmental disorders, providing both in-hospital and home-based digital therapy [1] - Data generated from the services will comply with local laws and regulations, ensuring data security and local storage without cross-border transmission [1] Group 2: Strategic Significance - The collaboration establishes a benchmark project for the company's digital therapy in the Hong Kong-Macau region, facilitating future expansion in the Greater Bay Area [2] - The partnership aims to accumulate high-quality real-world data for further scientific research on cognitive function diseases, enhancing diagnostic services and product iterations [2] - The initiative addresses urgent health needs in Macau, potentially reducing the incidence of severe dementia and creating sustainable service revenue for the company [2] Group 3: Academic and Research Collaboration - The cooperation enriches the company's ecosystem by integrating resources from authoritative medical institutions, promoting the standardization and large-scale application of cognitive digital therapies [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 與澳門鏡湖醫院簽署腦健康數字AI技術服務合作協議 本公告乃腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，旨在知會本公司股東及潛在投資者本集團於港澳地區之最新業務發展。 本公司董事會（「董事會」）欣然宣佈，本公司之間接全資附屬公司－腦動極光醫學 科技數智（澳門）有限公司（「腦動極光澳門」），已於近期與澳門鏡湖醫院（「鏡湖 醫院」）正式簽署《腦健康數字AI技術服務合作協議》（「該協議」）。雙方將圍繞認 知障礙的數字篩查、評估、訓練及全程健康管理，在澳門地區建立長期戰略合作 關係，共同構建覆蓋「醫院 － 社區 － 家居」的全鏈條腦健康服務新模式（「本次合 作」）。 一、合作背景 董事會認為，本次合作對本集團 ...

Core Viewpoint - ZTan Limited, a company wholly owned by the company's executive director and chairman, has voluntarily committed to a lock-up agreement regarding its direct equity in the company, demonstrating confidence in the company's long-term development and value [1] Group 1 - ZTan Limited has issued a voluntary commitment letter regarding its direct equity in the company [1] - The number of shares subject to the lock-up agreement is approximately 275 million shares [1] - The expiration date for the lock-up agreement is set for February 5, 2027 [1] Group 2 - The board believes that the lock-up commitment reflects ZTan Limited's strong confidence in the company's long-term development [1] - The commitment signifies support for the group's long-term value and development prospects [1]

Core Viewpoint - ZTan Limited, a company wholly owned by the executive director and chairman of the board of Brainstorm Aurora-B (06681), has voluntarily committed to a lock-up agreement regarding its direct equity in the company, reflecting confidence in the company's long-term development and value [1] Group 1 - ZTan Limited has committed to a lock-up agreement for approximately 275 million shares, with the final date of the lock-up being February 5, 2027 [1] - The board believes that this commitment demonstrates ZTan Limited's strong confidence in the long-term development and prospects of the company [1]

Core Viewpoint - ZTan Limited, a company wholly owned by the executive director and chairman of the board, has voluntarily committed to a lock-up agreement regarding its direct interest in the shares of the company, reflecting confidence in the company's long-term development and support for its value and prospects [1] Group 1 - ZTan Limited has issued a voluntary commitment letter on February 5, 2026, regarding its direct interest in the company's shares [1] - The company, along with its concert parties, is deemed to hold rights to approximately 519 million shares, representing about 38.18% of the company's total issued share capital [1] - The board believes that the lock-up commitment demonstrates ZTan Limited's strong confidence in the company's long-term development and its steadfast support for the group's long-term value and growth prospects [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券的邀請或要約。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） 本公司董事（「董事」，單獨為「董事」）會（「董事會」）茲通告，於2026年2月5日， 本公司接獲由ZTan Limited（一間由本公司執行董事、董事會主席兼首席策略官譚 錚先生全資擁有的英屬處女群島公司）發出的自願承諾函，內容關於ZTan Limited 已自願承諾就其於本公司股份（「股份」）的直接權益，接受僅以本公司為受益人的 禁售承諾（「禁售承諾」）。禁售承諾的詳情載列如下： | | 截至本公告日期 | | | --- | --- | --- | | 截至本公告日期 | 受禁售承諾規限 | | | 受禁售承諾規限 | 之股份佔本公司 | 受禁售承諾規限 | | 之股份數目 | 股權之概約百 ...

Market Overview - The Hang Seng Index opened lower but managed to close up by 0.14% [1] - The geopolitical situation remains stable, with Iran set to negotiate nuclear issues with the U.S. on February 6 [1] - Gold and silver prices fell significantly, with silver dropping over 14% and gold falling more than 2% to below $4,900 per ounce [1] International Relations - Russian President Putin plans to visit China in the first half of 2026 following a video call with Chinese leaders [2] - U.S. and Chinese leaders had a positive discussion regarding regional issues and economic cooperation, with a planned visit by Trump to China in April [2] - China has requested state-owned enterprises to pause new investment projects in Panama [2] Technology Sector - Despite declines in U.S. tech stocks, some Chinese tech companies like Naxin Micro (02676) reported strong earnings and plan to raise product prices by 10%-25% [3] - Baidu (09888) announced a stock buyback plan of up to $5 billion and plans to introduce a dividend policy by 2026, leading to a nearly 3% increase in its stock price [3] - Xiaomi (01810) repurchased shares worth HKD 146 million, also seeing a nearly 3% rise [3] - Tencent (00700) is expected to maintain double-digit growth in its gaming business by 2026, with advertising revenue projected to grow around 20% [3] Consumer Sector - Kweichow Moutai (600519.SH) has shown strong performance, boosting consumer valuations [4] - Oriental Selection (01797) surged over 10% due to its unique brand and membership model [4] - Pop Mart (09992) reported significant demand for its new products, with resale prices on secondary markets showing substantial premiums [4] Restaurant Sector - Yum China (09987) reported total revenue of $11.797 billion for 2025, a 4% increase year-on-year, with net profit rising by 2% [5] - Haidilao (06862) is seeing positive impacts from the return of its founder, with plans for expansion and new brand growth [5] - Brainstorm Aurora-B (06681) announced a strategic partnership to promote digital health products in Southeast Asia, with a significant stock price increase of over 15% [6] Energy Sector - The U.S. is experiencing a surge in natural gas power generation capacity, with over 29 GW under construction, but many projects may face delays due to a lack of available gas turbines [7] - Companies like Eagle Precision (01286) and Dongfang Electric (01072) are positioned to benefit from this trend, with expectations of increased demand for gas turbine components [7] Aviation Sector - Cirrus Aircraft (02507) launched the new G3 Vision Jet, enhancing its product line and expected to improve profit margins [8] - The new jet model is designed for private and corporate users, featuring significant upgrades in safety and comfort [8] - Cirrus is projected to deliver approximately 800 aircraft in 2025, with new orders expected to reach around 600 units [9]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； 公司名稱： 腦動極光醫療科技有限公司（於開曼群島註冊成立的有限公司） 呈交日期： 2026年2月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | ...

Core Viewpoint - The company has entered a strategic partnership with Silk Road Technology Co., Ltd. to promote cognitive impairment digital therapy products in Malaysia and Southeast Asia, addressing the growing demand for mental health solutions in the region [1][4]. Group 1: Partnership Details - The collaboration will focus on establishing a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road assisting in local approvals and logistics while the company provides technical and research support [3]. - The partnership includes applying for national innovation pilot projects, with Silk Road leading the engagement with Malaysian authorities [3]. - Clinical pilot projects will be initiated in selected hospitals, with the company responsible for local adaptation, training, and data collection [3]. Group 2: Market Context - Malaysia faces challenges with an aging population and increasing mental health needs, with 3.8 million people aged 60 and above as of 2023 [1]. - The country has a significant shortage of mental health resources, with a counselor-to-population ratio of 1:52,000, far below the international standard of 1:500 [1]. Group 3: Strategic Importance - This partnership marks the company's official entry into the Malaysian market, expanding its Southeast Asian business network and leveraging its experience in the Chinese market [4]. - Silk Road's extensive local resources and networks will facilitate efficient product entry and market adaptation, enhancing commercial conversion rates [4]. - The collaboration aims to strengthen the company's brand authority in digital healthcare and accelerate the deployment of its products in local medical institutions [4].

Core Viewpoint - The company Brainstorm Cell Therapeutics (06681) has seen a stock increase of over 13% following the announcement of a strategic partnership with Silk Road Technology Co., Ltd. to expand its digital therapy products in Malaysia and Southeast Asia [1] Group 1 - The strategic cooperation agreement aims to localize, promote, and transform research related to cognitive impairment digital therapy products in the Malaysian and Southeast Asian markets [1] - The board believes this partnership marks the company's official entry into the Malaysian market, further expanding its Southeast Asian business network [1] - The collaboration is expected to leverage the company's validated digital therapy experience and technology from the Chinese market to enhance its brand influence and business coverage internationally [1]